Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of KYN-5356 as Adjunctive Treatment in Adults With Cognitive Impairment Associated With Schizophrenia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KYN 5356 (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kynexis

Most Recent Events

  • 19 Aug 2026 According to a Kynexis media release, the company announced the closing of a Euro 40 million Series A extension. The financing will support close-out activities for the Phase 2 proof-of-concept study of KYN-5356.
  • 19 Aug 2026 According to a Kynexis media release, company has completed enrollment in ongoing Phase 2 proof-of-concept study in CIAS and remains on track to report topline results by the end of 2026. The trial enrolled across 13 clinical sites in the United States.
  • 19 Aug 2026 Status changed from recruiting to active, no longer recruiting, according to a Kynexis media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top